Vogenx, Inc. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Vogenx completed an $93.4M IPO in August 2026, issuing 7,187,500 shares at $13/share and netting $84.4M after underwriting costs. As of September 30, 2026, cash and marketable securities totaled $82.1M versus $601k at year-end 2025. Q3 2026 net loss was $4.9M ($0.47/share) versus $284k ($0.05/share) in Q3 2025, driven by $1.8M operating expenses and a $3.4M warrant liability mark-to-market loss.
Why this rating
IPO transformed a $681k company into one with $82.1M liquid assets—120x increase. Funded clinical advancement (EMERGE Phase 2b initiated) and hired leadership. Massive relative to pre-IPO scale; enables multi-year operations and development pipeline execution.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -2.70% over 4 hrs, n=20). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $18.23 | +10 min · unknown $18.16 ▼ 0.41% | +30 min · unknown $18.43 ▲ 1.10% | +1 hr · unknown $18.81 ▲ 3.18% | +4 hrs · unknown $17.71 ▼ 2.85% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.